CHEK1 and Miyoshi myopathy: The ATM/ATR-CHK1/2 signaling cascades activated by MEDI2228 treatment increase NKG2D ligands in MM cells and primes MM cells to natural killer (NK) cell-mediated cytotoxicity by increasing expression of MICA/B in MM cells to enhance binding and activating NK cytolytic activity.